Eli Lilly And Company ((LLY)) announced an update on their ongoing clinical study.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Eli Lilly and Company is conducting a Phase 3 clinical study titled EMBER-3 to evaluate the effectiveness of Imlunestrant, both alone and in combination with Abemaciclib, compared to standard endocrine therapies in patients with advanced estrogen receptor-positive, HER2-negative breast cancer. The study aims to determine the progression-free survival and overall response rates among different treatment groups, providing insights into potential new treatment options for this patient population.
The study involves three treatment arms: Imlunestrant alone, standard endocrine therapy (investigator’s choice between Exemestane or Fulvestrant), and a combination of Imlunestrant with Abemaciclib. These interventions are designed to assess their efficacy in slowing disease progression and improving patient outcomes.
This interventional study is randomized with a parallel assignment model and no masking, focusing primarily on treatment efficacy. The study’s primary goal is to evaluate progression-free survival, with secondary outcomes including overall response rates and duration of response.
The study began on October 4, 2021, with primary completion expected by June 2025 and overall completion by July 2025. The latest update was submitted in July 2025, indicating ongoing analysis and data collection.
The results of this study could significantly impact Eli Lilly’s market position, potentially boosting investor confidence and stock performance if the outcomes demonstrate a clear advantage over existing therapies. This could also influence the competitive landscape in the oncology sector, particularly for companies focusing on breast cancer treatments.
The study is currently active but not recruiting, with further details available on the ClinicalTrials portal.